CRIS Current Research Information System

ALTAVILLA, AMELIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.940
NA - Nord America 987
EU - Europa 432
SA - Sud America 140
Continente sconosciuto - Info sul continente non disponibili 70
AF - Africa 60
OC - Oceania 5
Totale 3.634
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 955
SG - Singapore 546
VN - Vietnam 463
CN - Cina 459
HK - Hong Kong 190
IT - Italia 151
BR - Brasile 109
KR - Corea 91
BD - Bangladesh 63
DE - Germania 62
FR - Francia 48
NL - Olanda 40
FI - Finlandia 33
IN - India 32
JP - Giappone 27
SC - Seychelles 25
GB - Regno Unito 23
SE - Svezia 22
AR - Argentina 13
PH - Filippine 11
CA - Canada 10
IQ - Iraq 10
MX - Messico 10
AT - Austria 9
IE - Irlanda 8
CI - Costa d'Avorio 7
CO - Colombia 7
ES - Italia 7
ID - Indonesia 7
TH - Thailandia 7
TR - Turchia 7
PL - Polonia 6
RU - Federazione Russa 6
AU - Australia 5
SA - Arabia Saudita 5
TW - Taiwan 5
ZA - Sudafrica 5
HN - Honduras 4
KE - Kenya 4
PK - Pakistan 4
CL - Cile 3
EC - Ecuador 3
MA - Marocco 3
UZ - Uzbekistan 3
AL - Albania 2
BE - Belgio 2
BG - Bulgaria 2
CH - Svizzera 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
EG - Egitto 2
ET - Etiopia 2
GR - Grecia 2
JM - Giamaica 2
JO - Giordania 2
MD - Moldavia 2
MU - Mauritius 2
MY - Malesia 2
PY - Paraguay 2
TG - Togo 2
TN - Tunisia 2
UA - Ucraina 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GH - Ghana 1
GT - Guatemala 1
KG - Kirghizistan 1
LT - Lituania 1
LY - Libia 1
MN - Mongolia 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.565
Salva come PNG Salva come JPEG
Città #
Singapore 374
Hefei 200
San Jose 181
Hong Kong 169
Ho Chi Minh City 130
Hanoi 128
Santa Clara 119
Ashburn 116
Seoul 85
Los Angeles 62
Beijing 61
Boardman 52
Council Bluffs 50
Buffalo 32
Da Nang 32
New York 31
Chandler 27
Helsinki 27
Tokyo 26
Lauterbourg 24
Bologna 21
Rome 21
Bengaluru 18
Haiphong 17
Milan 17
Munich 16
Falkenstein 11
Frankfurt am Main 11
Chicago 10
Nuremberg 10
Shenzhen 9
Dublin 8
London 8
Abidjan 7
Dallas 7
Guangzhou 7
Shanghai 7
Turin 7
Baghdad 6
Rio de Janeiro 6
Thái Nguyên 6
Tongling 6
Charlotte 5
Düsseldorf 5
Nha Trang 5
Redondo Beach 5
Warsaw 5
Bexley 4
Biên Hòa 4
Bắc Ninh 4
Bến Tre 4
Changsha 4
Florence 4
Genoa 4
Johannesburg 4
Lappeenranta 4
Mexico City 4
Nairobi 4
Naples 4
Orem 4
Phoenix 4
Princeton 4
Salt Lake City 4
San Francisco 4
Santo André 4
Stockholm 4
São Paulo 4
Wuhan 4
Bangkok 3
Brooklyn 3
Bắc Giang 3
Curitiba 3
Denver 3
Harbin 3
Huế 3
Jakarta 3
Lang Son 3
Marseille 3
Melbourne 3
Miami 3
Ninh Bình 3
Pescara 3
Recife 3
Tampa 3
Vienna 3
Việt Trì 3
Vũng Tàu 3
Addis Ababa 2
Ankara 2
Ann Arbor 2
Antioch 2
Athens 2
Baltimore 2
Baoding 2
Bari 2
Berlin 2
Bern 2
Bogotá 2
Bolzano 2
Boston 2
Totale 2.354
Salva come PNG Salva come JPEG
Nome #
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 216
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 203
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 194
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 162
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 147
PATIENT'S ATTITUDES TOWARDS TREATMENT IN ADVANCED CANCER: HOW THESE ARE IDENTIFIED FROM THEIR PHYSICIAN? 111
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 109
CAR-T cell therapy: A potential new strategy against prostate cancer 106
Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA) 106
ANTIANGIOGENIC AGENTS ARE INEFFECTIVE TO INCREASE COMPLETE RESPONSE RATE IN MRCC. A META-ANALYSIS 102
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 101
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support 98
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses 94
RELATIONSHIP BETWEEN ENZALUTAMIDE ACTIVITY AND PREVIOUS ANTIANDROGEN WITHDRAWAL SYNDROME (AWS) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) 92
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 92
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group 91
BENEFIT OF POST-DOCETAXEL TREATMENT IN CASTRATION RESISTANT PROSTATE CANCER PATIENTS WITH POOR PERFORMANCE STATUS 87
KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 87
Predicting positive bone marrow biopsies (BMBs) in patients (PTS) with advanced prostate cancer (APC) 84
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study 79
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 79
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate 72
Clinical and pathological features of primary renal synovial sarcoma: Analysis of 64 cases from 11 years of medical literature 71
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone 69
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)] 69
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 68
ERLOTINIB RELATED TOXICITY IN ELDERLY PATIENTS AFFECTED BY NON-SMALL CELL LUNG CANCER (NSCLC) 68
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents 67
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 67
Dynamic Contrast-enhanced Magnetic Resonance Imaging in the Early Evaluation of Anti-angiogenic Therapy in Metastatic Renal Cell Carcinoma 65
Visceral disease in castration-resistant prostate cancer 62
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 60
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 53
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies 49
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation 49
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy 47
Clinical and pathological features of primary neuroectodermal tumor/ewing sarcoma of the kidney 43
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant 36
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant 34
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone 30
Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma 28
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: A personal view 23
Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules 22
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 21
Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert 19
null 2
Totale 3.634
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.446
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.446
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202239 0 0 0 0 0 0 6 1 1 10 12 9
2022/202362 4 10 2 10 7 9 0 1 11 0 3 5
2023/202440 2 3 1 0 1 6 0 15 5 1 2 4
2024/2025875 55 84 41 46 175 54 34 27 7 67 46 239
2025/20262.449 191 302 180 206 212 49 415 149 393 123 131 98
2026/2027169 84 85 0 0 0 0 0 0 0 0 0 0
Totale 3.634